Want to see CTOR full AI Analyst Report?
CTOR Stock Chart & Stats
$0.56
>-$0.01(-1.10%)
At close: 4:00 PM EDT
$0.56
>-$0.01(-1.10%)
Day’s Range― - ―
52-Week Range$0.49 - $2.25
Previous Close$0.56
Volume32.62K
Average Volume (3M)56.61K
Market Cap
$55.07M
Enterprise Value$63.17
Total Cash (Recent Filing)$2.63M
Total Debt (Recent Filing)$3.80M
Price to Earnings (P/E)―
Beta1.38
Next Earnings
Aug 18, 2026EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.47
Shares Outstanding92,981,200
10 Day Avg. Volume44,100
30 Day Avg. Volume56,609
Financial Highlights & Ratios
PEG Ratio-0.45
Price to Book (P/B)3.32
Price to Sales (P/S)0.00
P/FCF Ratio-27.08
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$4.00Price Target Upside614.29% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.52
Revenue Forecast (FY)$20.82M
Bulls Say, Bears Say
Bulls Say
Promising Clinical Efficacy And Expansion PotentialDurable responses and a 24% overall response rate in a heavily pretreated population indicate meaningful clinical activity for LYMPHIR combos. Planned Phase 2 expansion and translational work could broaden the label beyond CTCL, increasing addressable market and long-term commercialization optionality.
Strengthened Near-term Liquidity For CommercializationA committed financing package sized to support sales-force, market access, manufacturing and working capital materially reduces immediate runway risk. That funding enables operational investments required to commercialize LYMPHIR and execute planned clinical expansions over the next several quarters.
Low Leverage Supports Financial FlexibilityRelatively low leverage gives management scope to fund R&D and commercialization without heavy interest burdens, improving ability to raise additional capital on less dilutive terms. This structural balance-sheet strength supports strategic optionality amid ongoing investment needs.
Bears Say
Pre-revenue Business ModelWith no product sales yet, CTOR must convert clinical outcomes into commercial uptake to generate sustainable cash flow. The company's long-term outlook depends on regulatory success, market access, and execution of launch plans—execution risks that materially affect viability over the coming months.
Rising Cash Burn And Negative Free Cash FlowWidening operating and free cash outflows increase reliance on external funding. Persistent negative FCF raises the probability of future financings that could dilute shareholders or impose restrictive terms, and constrains the firm's ability to sustain simultaneous commercialization and clinical programs.
Widening Losses And Equity ErosionMaterial deterioration in operating results and shrinking equity indicate ongoing capital consumption and negative returns on invested capital. Continued losses erode shareholder equity and heighten refinancing risk, reducing tolerance for execution delays in clinical development or market launch.
Citius Oncology News
CTOR FAQ
What was Citius Oncology’s price range in the past 12 months?
Citius Oncology lowest stock price was $0.49 and its highest was $2.25 in the past 12 months.
What is Citius Oncology’s market cap?
Citius Oncology’s market cap is $55.07M.
When is Citius Oncology’s upcoming earnings report date?
Citius Oncology’s upcoming earnings report date is Aug 18, 2026 which is in 13 days.
How were Citius Oncology’s earnings last quarter?
Citius Oncology released its earnings results on May 15, 2026. The company reported -$0.27 earnings per share for the quarter, missing the consensus estimate of -$0.01 by -$0.26.
Is Citius Oncology overvalued?
According to Wall Street analysts Citius Oncology’s price is currently Undervalued.
Does Citius Oncology pay dividends?
Citius Oncology does not currently pay dividends.
What is Citius Oncology’s EPS estimate?
Citius Oncology’s EPS estimate is -0.04.
How many shares outstanding does Citius Oncology have?
Citius Oncology has 92,981,200 shares outstanding.
What happened to Citius Oncology’s price movement after its last earnings report?
Citius Oncology reported an EPS of -$0.27 in its last earnings report, missing expectations of -$0.01. Following the earnings report the stock price went down -14.019%.
Which hedge fund is a major shareholder of Citius Oncology?
Currently, no hedge funds are holding shares in CTOR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Citius Oncology Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.00 (614.29% Upside)
$4.00 (614.29% Upside)
Blogger Sentiment
Bullish
CTOR Sentiment 100%
Sector Average ―
Sector Average ―
Technicals
SMA
Negative
20 days / 200 days
Momentum
-78.73%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
10.13%
Trailing 12-Months
Company Description
Citius Oncology
Citius Oncology, Inc. concentrates on advancing innovative, targeted therapeutic solutions for various cancer types. A key aspect of its pipeline includes the development of LYMPHIR, an investigational orphan drug intended to treat adults battling cutaneous T-cell lymphoma that has either relapsed or is unresponsive to existing therapies. The firm's main offices are situated in New York, New York. Citius Oncology, Inc. functions as a division of its parent company, Citius Pharmaceuticals, Inc.
CTOR Stock 12 Month Forecast
Average Price Target
$4.00
▲(614.29% Upside)
Technical Analysis
Ownership Overview
6.58% Insiders
0.79% Mutual Funds
9.88% Other Institutional Investors
82.16% Public Companies and
Individual Investors